Press Release Archives 2012
Investor Relations Home
Companion animals are living longer and therefore are at higher risk of developing an increasing number of medical conditions such as allergies, arthritis, diabetes, cancer and obesity; however, few treatment options exist for these conditions today.
Aratana is positioned to address this need for better pet care by bringing human science to animal health and providing veterinarians with innovative new medicines that have been designed specifically for treating pets.
Aratana’s unique “pet-centric” approach differs fundamentally from the current standard, which often involves adjusting the dose of marketed human drugs, which are only presumed to be safe and effective in animals based on human data and veterinary experience. There is significant demand amongst veterinarians and pet owners for higher quality medicines that have been specifically studied and approved by regulatory authorities for each species. Aratana’s team of drug development and commercial experts are dedicated to developing innovative treatments in accordance with regulatory standards to meet these needs.
Mission and Strategy
Aratana's mission is to find, develop and commercialize safe and effective therapeutics to enhance the quality of life and strengthen the bond between people and their pets. Our strategy is to become the leading provider of therapeutics developed and approved specifically for the treatment of unmet medical needs in pets. We intend to help shape and define the pet therapeutics market by identifying, acquiring and developing high-value commercial products for companion animals in a cost effective and efficient manner.
Aratana is currently developing several compounds for the large and growing pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence, and a recently licensed non-opioid local anesthetic for treating post-operative pain. These compounds, which are being developed individually for both cats and dogs, are supported by substantial safety and efficacy data and, if approved by regulatory authorities, could become best- or first-in-class products in the animal health industry.
The company is actively identifying additional programs to in-license from human health companies in order to expand its development pipeline of animal medicines.